Cell cycle control by the insulin-like growth factor signal: at the crossroad between cell growth and mitotic regulation

References

• Fujita-Yamaguchi Y, Choi S, Sakamoto Y, et al. Purification of insulin receptor with full binding activity. J Biol Chem. 1983 Apr 25;258(8):5045–5049.
   PubMed Web of Science ®Google Scholar
• Kasuga M, Fujita-Yamaguchi Y, Blithe DL, et al. Tyrosine-specific protein kinase activity is associated with the purified insulin receptor. Proc Natl Acad Sci U S A. 1983 Apr;80(8):2137–2141.
   PubMed Web of Science ®Google Scholar
• Ebina Y, Ellis L, Jarnagin K, et al. The human insulin receptor cDNA: the structural basis for hormone-activated transmembrane signalling. Cell. 1985 Apr;40(4):747–758.
   PubMed Web of Science ®Google Scholar
• Ullrich A, Bell JR, Chen EY, et al. Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. Nature. 1985 Feb-Mar 28-06;313(6005):756–761.
   PubMed Web of Science ®Google Scholar
• LeBon TR, Jacobs S, Cuatrecasas P, et al. Purification of insulin-like growth factor I receptor from human placental membranes. J Biol Chem. 1986 Jun 15;261(17):7685–7689.
   PubMed Web of Science ®Google Scholar
• Ullrich A, Gray A, Tam AW, et al. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J. 1986 Oct;5(10):2503–2512.
   PubMed Web of Science ®Google Scholar
• Hunter T. The proteins of oncogenes. Sci Am. 1984 Aug;251(2):70–79.
   PubMed Web of Science ®Google Scholar
• Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999 Jun 15;13(12):1501–1512.
   PubMed Web of Science ®Google Scholar
• Uhlen M, Fagerberg L, Hallstrom BM, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015 Jan 23;347(6220):1260419.
   PubMed Web of Science ®Google Scholar
• Scalia P, Giordano A, Martini C, et al. Isoform- and Paralog-Switching in IR-Signaling: When Diabetes Opens the Gates to Cancer. Biomolecules. 2020 Nov 30;10(12):1617.
   PubMed Web of Science ®Google Scholar
• Grandjean V, Smith J, Schofield PN, et al. Increased IGF-II protein affects p57kip2 expression in vivo and in vitro: implications for Beckwith-Wiedemann syndrome. Proc Natl Acad Sci U S A. 2000 May 9;97(10):5279–5284.
   PubMed Web of Science ®Google Scholar
• Morison IM, Becroft DM, Taniguchi T, et al. Somatic overgrowth associated with overexpression of insulin-like growth factor II. Nat Med. 1996 Mar;2(3):311–316.
   PubMed Web of Science ®Google Scholar
• Kim SY, Lee SM, Kwon GE, et al. Maternal dyslipidemia and altered cholesterol metabolism in early pregnancy as a risk factor for small for gestational age neonates. Sci Rep. 2021 Oct 26;11(1):21066.
   PubMed Web of Science ®Google Scholar
• Cooke NE, et al. Normal and aberrant growth in children. Melmed S, Koenig R, Rosen C, et al., editors. Williams Textbook of Endocrinology. 13th. Vol. 25, Philadelphia PA: Elsevier; 2016:964–1073.
   Google Scholar
• Menon RK, Sperling MA. Insulin as a growth factor. Endocrinol Metab Clin North Am. 1996 Sep;25(3):633–647.
   PubMed Web of Science ®Google Scholar
• Chao W, D’Amore PA. IGF2: epigenetic regulation and role in development and disease. Cytokine Growth Factor Rev. 2008 Apr;19(2):111–120.
   PubMed Web of Science ®Google Scholar
• Holly JMP, Biernacka K, Perks CM. The Neglected Insulin: IGF-II, a Metabolic Regulator with Implications for Diabetes, Obesity, and Cancer. Cells. 2019 Oct 6;8(10):1207.
   PubMed Web of Science ®Google Scholar
• Halje M, Nordin M, Bergman D, et al. Review: The effect of insulin-like growth factor II in the regulation of tumour cell growth in vitro and tumourigenesis in vivo. Vivo. 2012 Jul-Aug;26(4):519–526.
   PubMed Web of Science ®Google Scholar
• Ziegler AN, Schneider JS, Qin M, et al. IGF-II promotes stemness of neural restricted precursors. Stem Cells. 2012 Jun;30(6):1265–1276.
   PubMed Web of Science ®Google Scholar
• Kimura G, Kasuya J, Giannini S, et al. Insulin-like growth factor (IGF) system components in human prostatic cancer cell-lines: LNCaP, DU145, and PC-3 cells. Int j urol. 1996 Jan;3(1):39–46.
   PubMedGoogle Scholar
• Sciacca L, Costantino A, Pandini G, et al. Insulin receptor activation by IGF-II in breast cancers: evidence for a new autocrine/paracrine mechanism. Oncogene. 1999 Apr 15;18(15):2471–2479.
   PubMed Web of Science ®Google Scholar
• Sciacca L, Mineo R, Pandini G, et al. In IGF-I receptor-deficient leiomyosarcoma cells autocrine IGF-II induces cell invasion and protection from apoptosis via the insulin receptor isoform A. Oncogene. 2002 Nov 28;21(54):8240–8250.
   PubMed Web of Science ®Google Scholar
• Pandini G, Frasca F, Mineo R, et al. Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J Biol Chem. 2002 Oct 18;277(42):39684–39695.
   PubMed Web of Science ®Google Scholar
• Yang L, Li J, Ran L, et al. Phosphorylated insulin-like growth factor 1 receptor is implicated in resistance to the cytostatic effect of gefitinib in colorectal cancer cells. J Gastrointest Surg. 2011 Jun;15(6):942–957.
   PubMed Web of Science ®Google Scholar
• Scalia P, Pandini G, Carnevale V, et al. Identification of a novel EphB4 phosphodegron regulated by the autocrine IGFII/IRA axis in malignant mesothelioma. Oncogene. 2019 Aug 01;38(31):5987–6001.
   PubMed Web of Science ®Google Scholar
• Quinn KA, Treston AM, Unsworth EJ, et al. Insulin-like growth factor expression in human cancer cell lines. J Biol Chem. 1996 May 10;271(19):11477–11483.
   PubMed Web of Science ®Google Scholar
• Christofori G, Naik P, Hanahan D. A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature. 1994 Jun 2;369(6479):414–418.
   PubMed Web of Science ®Google Scholar
• Ulanet DB, Ludwig DL, Kahn CR, et al. Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy. Proc Natl Acad Sci U S A. 2010 Jun 15;107(24):10791–10798.
   PubMed Web of Science ®Google Scholar
• Scalia P, Giordano A, Williams SJ. The IGF-II-Insulin Receptor Isoform-A; Autocrine Signal in Cancer: Actionable Perspectives. Cancers (Basel). 2020 Feb 5;12(2):366.
   PubMed Web of Science ®Google Scholar
• Kaneda A, Wang CJ, Cheong R, et al. Enhanced sensitivity to IGF-II signaling links loss of imprinting of IGF2 to increased cell proliferation and tumor risk. Proc Natl Acad Sci U S A. 2007;104(52):20926–20931.
   PubMed Web of Science ®Google Scholar
• Humbel RE. Insulin-like growth factors I and II. Eur J Biochem. 1990 Jul 5;190(3):445–462.
   PubMedGoogle Scholar
• Ballard FJ, Read LC, Francis GL, et al. Binding properties and biological potencies of insulin-like growth factors in L6 myoblasts. Biochem J. 1986 Jan 1;233(1):223–230.
   PubMed Web of Science ®Google Scholar
• Daughaday WH, Hall K, Raben MS, et al. Somatomedin: proposed designation for sulphation factor. Nature. 1972 Jan 14;235(5333):107.
   PubMed Web of Science ®Google Scholar
• Morgan DO, Edman JC, Standring DN, et al. Insulin-like growth factor II receptor as a multifunctional binding protein. Nature. 1987 Sep 24-30;329(6137):301–307.
   PubMed Web of Science ®Google Scholar
• MacDonald RG, Pfeffer Suzanne R, Coussens L, et al. A Single Receptor Binds Both Insulin-Like Growth Factor II and Mannose-6-Phosphate. Science. 1988 Mar 04;239(4844):1134–1137.
   PubMed Web of Science ®Google Scholar
• Mottola C, MacDonald RG, Brackett JL, et al. Purification and amino-terminal sequence of an insulin-like growth factor-binding protein secreted by rat liver BRL-3A cells. J Biol Chem. 1986 Aug 25;261(24):11180–11188.
   PubMed Web of Science ®Google Scholar
• Roth RA. Structure of the Receptor for Insulin-Like Growth Factor II: The Puzzle Amplified. Science. 1988 Mar 11;239(4845):1269–1271.
   PubMed Web of Science ®Google Scholar
• Oates AJ, Schumaker LM, Jenkins SB, et al. The mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R), a putative breast tumor suppressor gene. Breast Cancer Res Treat. 1998 Feb;47(3):269–281.
   PubMed Web of Science ®Google Scholar
• O’Gorman DB, Costello M, Weiss J, et al. Decreased insulin-like growth factor-II/mannose 6-phosphate receptor expression enhances tumorigenicity in JEG-3 cells. Cancer Res. 1999 Nov 15;59(22):5692–5694.
   PubMed Web of Science ®Google Scholar
• Chen Z, Ge Y, Landman N, et al. Decreased expression of the mannose 6-phosphate/insulin-like growth factor-II receptor promotes growth of human breast cancer cells. BMC cancer. 2002 Jul 30;2(1):18.
   PubMedGoogle Scholar
• Hughes J, Surakhy M, Can S, et al. Maternal transmission of an Igf2r domain 11: IGF2 binding mutant allele (Igf2r(I1565A)) results in partial lethality, overgrowth and intestinal adenoma progression. Sci Rep. 2019;9(1):11388.
   PubMedGoogle Scholar
• Hankins GR, De Souza AT, Bentley RC, et al. M6P/IGF2 receptor: a candidate breast tumor suppressor gene. Oncogene. 1996 May 2;12(9):2003–2009.
   PubMed Web of Science ®Google Scholar
• Casella SJ, Han VK, D’Ercole AJ, et al. Insulin-like growth factor II binding to the type I somatomedin receptor. Evidence for two high affinity binding sites. J Biol Chem. 1986 Jul 15;261(20):9268–9273.
   PubMed Web of Science ®Google Scholar
• Papa V, Pezzino V, Costantino A, et al. Elevated insulin receptor content in human breast cancer. J Clin Invest. 1990 Nov;86(5):1503–1510.
   PubMed Web of Science ®Google Scholar
• Milazzo G, Giorgino F, Damante G, et al. Insulin receptor expression and function in human breast cancer cell lines. Cancer Res. 1992 Jul 15;52(14):3924–3930.
   PubMed Web of Science ®Google Scholar
• Frittitta L, Vigneri R, Stampfer MR, et al. Insulin receptor overexpression in 184B5 human mammary epithelial cells induces a ligand-dependent transformed phenotype. J Cell Biochem. 1995 Apr;57(4):666–669.
   PubMed Web of Science ®Google Scholar
• Milazzo G, Yip CC, Maddux BA, et al. High-affinity insulin binding to an atypical insulin-like growth factor-I receptor in human breast cancer cells. J Clin Invest. 1992 Mar;89(3):899–908.
   PubMed Web of Science ®Google Scholar
• Pezzino V, Papa V, Milazzo G, et al. Insulin-like growth factor-I (IGF-I) receptors in breast cancer. Ann N Y Acad Sci. 1996 Apr 30;784(1 Challenges an):189–201.
   PubMedGoogle Scholar
• Massague J, Blinderman LA, Czech MP. The high affinity insulin receptor mediates growth stimulation in rat hepatoma cells. J Biol Chem. 1982 Dec 10;257(23):13958–13963.
   PubMed Web of Science ®Google Scholar
• McFarland DC. Nutritional and developmental roles of insulin-like growth factors between species: a brief history and introduction. J Nutr. 1998 Feb;128(2 Suppl):300S–301S.
   PubMed Web of Science ®Google Scholar
• Bailyes EM, Nave BT, Soos MA, et al. Insulin receptor/IGF-I receptor hybrids are widely distributed in mammalian tissues: quantification of individual receptor species by selective immunoprecipitation and immunoblotting. Biochem J. 1997 Oct 1;327(Pt 1):209–215.
   PubMedGoogle Scholar
• Louvi A, Accili D, Efstratiadis A. Growth-promoting interaction of IGF-II with the insulin receptor during mouse embryonic development. Dev Biol. 1997 Sep 1;189(1):33–48.
   PubMed Web of Science ®Google Scholar
• Frasca F, Pandini G, Scalia P, et al. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol. 1999 May;19(5):3278–3288.
   PubMed Web of Science ®Google Scholar
• Dynkevich Y, Rother KI, Whitford I, et al. Tumors, IGF-2, and hypoglycemia: insights from the clinic, the laboratory, and the historical archive. Endocr Rev. 2013 Dec;34(6):798–826.
   PubMed Web of Science ®Google Scholar
• Morcavallo A, Gaspari M, Pandini G, et al. Research resource: New and diverse substrates for the insulin receptor isoform A revealed by quantitative proteomics after stimulation with IGF-II or insulin. Mol Endocrinol. 2011 Aug;25(8):1456–1468.
   PubMedGoogle Scholar
• Pandini G, Medico E, Conte E, et al. Differential gene expression induced by insulin and insulin-like growth factor-II through the insulin receptor isoform A. J Biol Chem. 2003 Oct 24;278(43):42178–42189.
   PubMed Web of Science ®Google Scholar
• Nagao H, Cai W, Wewer Albrechtsen NJ, et al. Distinct signaling by insulin and IGF-1 receptors and their extra- and intracellular domains. Proc Natl Acad Sci U S A. 2021 Apr 27;118(17). DOI:10.1073/pnas.2019474118
   PubMed Web of Science ®Google Scholar
• Rotwein P. The complex genetics of human insulin-like growth factor 2 are not reflected in public databases. J Biol Chem. 2018 Mar 23;293(12):4324–4333.
   PubMed Web of Science ®Google Scholar
• Baserga R. The decline and fall of the IGF-I receptor. J Cell Physiol. 2013 Apr;228(4):675–679.
   PubMed Web of Science ®Google Scholar
• Allard JB, Duan C. IGF-Binding Proteins: Why Do They Exist and Why Are There So Many? Front Endocrinol (Lausanne). 2018 Apr 09;9:9. DOI:10.3389/fendo.2018.00009
   PubMed Web of Science ®Google Scholar
• Forbes B, McCarthy P, Norton R. Insulin-Like Growth Factor Binding Proteins: A Structural Perspective. Front Endocrinol (Lausanne). 2012 Mar 02;3:3. DOI:10.3389/fendo.2012.00003
   PubMedGoogle Scholar
• Gupta MB. The role and regulation of IGFBP-1 phosphorylation in fetal growth restriction. J Cell Commun Signal. 2015;9(2):111–123.
   PubMed Web of Science ®Google Scholar
• Lin YW, Weng XF, Huang BL, et al. IGFBP-1 in cancer: expression, molecular mechanisms, and potential clinical implications. Am J Transl Res. 2021;13(3):813–832.
   PubMed Web of Science ®Google Scholar
• Gray A, Aronson WJ, Barnard RJ, et al. Global Igfbp1 deletion does not affect prostate cancer development in a c-Myc transgenic mouse model. J Endocrinol. 2011 Dec;211(3):297–304.
   PubMed Web of Science ®Google Scholar
• Duan C, Ding J, Li Q, et al. Insulin-like growth factor binding protein 2 is a growth inhibitory protein conserved in zebrafish. Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15274–15279.
   PubMed Web of Science ®Google Scholar
• Wood TL, Rogler LE, Czick ME, et al. Selective alterations in organ sizes in mice with a targeted disruption of the insulin-like growth factor binding protein-2 gene. Mol Endocrinol. 2000 Sep;14(9):1472–1482.
   PubMedGoogle Scholar
• Pickard A, McCance DJ. IGF-Binding Protein 2 - Oncogene or Tumor Suppressor? Front Endocrinol (Lausanne). 2015;6:25.
   PubMed Web of Science ®Google Scholar
• Mehta HH, Gao Q, Galet C, et al. IGFBP-3 is a metastasis suppression gene in prostate cancer. Cancer Res. 2011;71(15):5154–5163.
   PubMed Web of Science ®Google Scholar
• Blouin M-J, Bazile M, Birman E, et al. Germ line knockout of IGFBP-3 reveals influences of the gene on mammary gland neoplasia. Breast Cancer Res Treat. 2015 Feb 01;149(3):577–585.
   PubMed Web of Science ®Google Scholar
• Lau MM, Stewart CE, Liu Z, et al. Loss of the imprinted IGF2/cation-independent mannose 6-phosphate receptor results in fetal overgrowth and perinatal lethality. Genes Dev. 1994 Dec 15;8(24):2953–2963.
   PubMed Web of Science ®Google Scholar
• Morrione A, Valentinis B, Xu SQ, et al. Insulin-like growth factor II stimulates cell proliferation through the insulin receptor. Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3777–3782.
   PubMed Web of Science ®Google Scholar
• Ludwig T, Eggenschwiler J, Fisher P, et al. Mouse Mutants Lacking the Type 2 IGF Receptor (IGF2R) Are Rescued from Perinatal Lethality inIgf2andIgf1rNull Backgrounds. Dev Biol. 1996 Aug 01;177(2):517–535.
   PubMed Web of Science ®Google Scholar
• Papa V, Russo P, Gliozzo B, et al. An intact and functional soluble form of the insulin receptor is secreted by cultured cells. Endocrinology. 1993;133(3):1369–1376.
   PubMed Web of Science ®Google Scholar
• Sun XJ, Rothenberg P, Kahn CR, et al. Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein. Nature. 1991 Jul 4;352(6330):73–77.
   PubMed Web of Science ®Google Scholar
• Araki E, Sun XJ, Haag BL 3rd, et al. Human skeletal muscle insulin receptor substrate-1. Characterization of the cDNA, gene, and chromosomal localization. Diabetes. 1993 Jul;42(7):1041–1054.
   PubMed Web of Science ®Google Scholar
• White MF. The insulin signalling system and the IRS proteins. Diabetologia. 1997 Jul;40(Suppl 2):S2–17.
   PubMedGoogle Scholar
• Valentinis B, Navarro M, Zanocco-Marani T, et al. Insulin receptor substrate-1, p70S6K, and cell size in transformation and differentiation of hemopoietic cells. J Biol Chem. 2000 Aug 18;275(33):25451–25459.
   PubMed Web of Science ®Google Scholar
• Kaburagi Y, Yamashita R, Ito Y, et al. Insulin-induced cell cycle progression is impaired in chinese hamster ovary cells overexpressing insulin receptor substrate-3. Endocrinology. 2004 Dec;145(12):5862–5874.
   PubMed Web of Science ®Google Scholar
• Ikink GJ, Hilkens J. Insulin receptor substrate 4 (IRS4) is a constitutive active oncogenic driver collaborating with HER2 and causing therapeutic resistance. Mol Cell Oncol. 2017;4(2):e1279722.
   PubMed Web of Science ®Google Scholar
• Shoelson SE, Chatterjee S, Chaudhuri M, et al. YMXM motifs of IRS-1 define substrate specificity of the insulin receptor kinase. Proc Natl Acad Sci U S A. 1992 Mar 15;89(6):2027–2031.
   PubMed Web of Science ®Google Scholar
• Skolnik EY, Lee CH, Batzer A, et al. The SH2/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated IRS1 and Shc: implications for insulin control of ras signalling. EMBO J. 1993 May;12(5):1929–1936.
   PubMed Web of Science ®Google Scholar
• Sawka-Verhelle D, Tartare-Deckert S, White MF, et al. Insulin receptor substrate-2 binds to the insulin receptor through its phosphotyrosine-binding domain and through a newly identified domain comprising amino acids 591-786. J Biol Chem. 1996 Mar 15;271(11):5980–5983.
   PubMed Web of Science ®Google Scholar
• Gustafson TA, He W, Craparo A, et al. Phosphotyrosine-dependent interaction of SHC and insulin receptor substrate 1 with the NPEY motif of the insulin receptor via a novel non-SH2 domain. Mol Cell Biol. 1995 May;15(5):2500–2508.
   PubMed Web of Science ®Google Scholar
• Ruderman NB, Kapeller R, White MF, et al. Activation of phosphatidylinositol 3-kinase by insulin. Proc Natl Acad Sci U S A. 1990 Feb;87(4):1411–1415.
   PubMed Web of Science ®Google Scholar
• Alessi DR, Andjelkovic M, Caudwell B, et al. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J. 1996 Dec 2;15(23):6541–6551.
   PubMed Web of Science ®Google Scholar
• Alessi DR, James SR, Downes CP, et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol. 1997 Apr 1;7(4):261–269.
   PubMed Web of Science ®Google Scholar
• Liu AX, Testa JR, Hamilton TC, et al. AKT2, a member of the protein kinase B family, is activated by growth factors, v-Ha-ras, and v-src through phosphatidylinositol 3-kinase in human ovarian epithelial cancer cells. Cancer Res. 1998 Jul 15;58(14):2973–2977.
   PubMed Web of Science ®Google Scholar
• Harrington LS, Findlay GM, Gray A, et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol. 2004 Jul 19;166(2):213–223.
   PubMed Web of Science ®Google Scholar
• Zhang HH, Lipovsky AI, Dibble CC, et al. S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt. Mol Cell. 2006 Oct 20;24(2):185–197.
   PubMed Web of Science ®Google Scholar
• Zhang J, Gao Z, Yin J, et al. S6K directly phosphorylates IRS-1 on Ser-270 to promote insulin resistance in response to TNF-(alpha) signaling through IKK2. J Biol Chem. 2008;283(51):35375–35382.
   PubMed Web of Science ®Google Scholar
• Shin S, Wolgamott L, Yu Y, et al. Glycogen synthase kinase (GSK)-3 promotes p70 ribosomal protein S6 kinase (p70S6K) activity and cell proliferation. Proc Natl Acad Sci U S A. 2011 Nov 22;108(47):E1204–13.
   PubMed Web of Science ®Google Scholar
• Copps KD, White MF. Regulation of insulin sensitivity by serine/threonine phosphorylation of insulin receptor substrate proteins IRS1 and IRS2. Diabetologia. 2012 Oct;55(10):2565–2582.
   PubMed Web of Science ®Google Scholar
• Scalia P, Heart E, Comai L, et al. Regulation of the Akt/Glycogen synthase kinase-3 axis by insulin-like growth factor-II via activation of the human insulin receptor isoform-A. J Cell Biochem. 2001;82(4):610–618.
   PubMed Web of Science ®Google Scholar
• Medema RH, de Vries-Smits Am, van der Zon Gc, et al. Ras activation by insulin and epidermal growth factor through enhanced exchange of guanine nucleotides on p21ras. Mol Cell Biol. 1993 Jan;13(1):155–162.
   PubMed Web of Science ®Google Scholar
• Yin Y, Hua H, Li M, et al. mTORC2 promotes type I insulin-like growth factor receptor and insulin receptor activation through the tyrosine kinase activity of mTOR. Cell Res. 2016 Jan;26(1):46–65.
   PubMed Web of Science ®Google Scholar
• Yoneyama Y, Inamitsu T, Chida K, et al. Serine Phosphorylation by mTORC1 Promotes IRS-1 Degradation through SCFbeta-TRCP E3 Ubiquitin Ligase. iScience. 2018 Jul 27;5:1–18. DOI:10.1016/j.isci.2018.06.006
   PubMed Web of Science ®Google Scholar
• Wu S, Zhou B, Xu L, et al. IRS-2, but not IRS-1, can sustain proliferation and rescue UBF stabilization in InR or InR defective signaling of 32D myeloid cells. Cell Cycle. 2009 Oct 1;8(19):3218–3226.
   PubMed Web of Science ®Google Scholar
• Xuan S, Szabolcs M, Cinti F, et al. Genetic analysis of type-1 insulin-like growth factor receptor signaling through insulin receptor substrate-1 and −2 in pancreatic beta cells. J Biol Chem. 2010;285(52):41044–41050.
   PubMed Web of Science ®Google Scholar
• Araki E, Lipes MA, Patti ME, et al. Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. Nature. 1994 Nov 10;372(6502):186–190.
   PubMed Web of Science ®Google Scholar
• Tamemoto H, Kadowaki T, Tobe K, et al. Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature. 1994 Nov 10;372(6502):182–186.
   PubMed Web of Science ®Google Scholar
• Bruning JC, Winnay J, Cheatham B, et al. Differential signaling by insulin receptor substrate 1 (IRS-1) and IRS-2 in IRS-1-deficient cells. Mol Cell Biol. 1997 Mar;17(3):1513–1521.
   PubMed Web of Science ®Google Scholar
• Rabiee A, Kruger M, Ardenkjaer-Larsen J, et al. Distinct signalling properties of insulin receptor substrate (IRS)-1 and IRS-2 in mediating insulin/IGF-1 action. Cell Signal. 2018 Jul;47:1–15.
   PubMed Web of Science ®Google Scholar
• Tartare-Deckert S, Sawka-Verhelle D, Murdaca J, et al. Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system. J Biol Chem. 1995 Oct 6;270(40):23456–23460.
   PubMed Web of Science ®Google Scholar
• Guo S, Dunn SL, White MF. The reciprocal stability of FOXO1 and IRS2 creates a regulatory circuit that controls insulin signaling. Mol Endocrinol. 2006 Dec;20(12):3389–3399.
   PubMedGoogle Scholar
• Shah OJ, Wang Z, Hunter T. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol. 2004 Sep 21;14(18):1650–1656.
   PubMed Web of Science ®Google Scholar
• Tzatsos A. Raptor binds the SAIN (Shc and IRS-1 NPXY binding) domain of insulin receptor substrate-1 (IRS-1) and regulates the phosphorylation of IRS-1 at Ser-636/639 by mTOR. J Biol Chem. 2009 Aug 21;284(34):22525–22534.
   PubMed Web of Science ®Google Scholar
• Kim SJ, DeStefano MA, Oh WJ, et al. mTOR complex 2 regulates proper turnover of insulin receptor substrate-1 via the ubiquitin ligase subunit Fbw8. Mol Cell. 2012 Dec 28;48(6):875–887.
   PubMed Web of Science ®Google Scholar
• Drakas R, Tu X, Baserga R. Control of cell size through phosphorylation of upstream binding factor 1 by nuclear phosphatidylinositol 3-kinase. Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9272–9276.
   PubMed Web of Science ®Google Scholar
• Ozoe A, Sone M, Fukushima T, et al. Insulin receptor substrate-1 associates with small nucleolar RNA which contributes to ribosome biogenesis. Front Endocrinol (Lausanne). 2014;5:24.
   PubMed Web of Science ®Google Scholar
• Piper AJ, Clark JL, Mercado-Matos J, et al. Insulin Receptor Substrate-1 (IRS-1) and IRS-2 expression levels are associated with prognosis in non-small cell lung cancer (NSCLC). PloS one. 2019;14(8):e0220567.
   PubMed Web of Science ®Google Scholar
• Luo X, Fan S, Huang W, et al. Downregulation of IRS-1 promotes metastasis of head and neck squamous cell carcinoma. Oncol Rep. 2012 Aug 01;28(2):659–667.
   PubMed Web of Science ®Google Scholar
• Manohar S, Yu Q, Gygi SP, et al. The Insulin Receptor Adaptor IRS2 is an APC/C Substrate That Promotes Cell Cycle Protein Expression and a Robust Spindle Assembly Checkpoint. Mol Cell Proteomics. 2020 Sep;19(9):1450–1467.
   PubMed Web of Science ®Google Scholar
• Lowenstein EJ, Daly RJ, Batzer AG, et al. The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling. Cell. 1992 Aug 7;70(3):431–442.
   PubMed Web of Science ®Google Scholar
• Li W, Nishimura R, Kashishian A, et al. A new function for a phosphotyrosine phosphatase: linking GRB2-Sos to a receptor tyrosine kinase. Mol Cell Biol. 1994 Jan;14(1):509–517.
   PubMed Web of Science ®Google Scholar
• Wick KR, Werner ED, Langlais P, et al. Grb10 inhibits insulin-stimulated insulin receptor substrate (IRS)-phosphatidylinositol 3-kinase/Akt signaling pathway by disrupting the association of IRS-1/IRS-2 with the insulin receptor. J Biol Chem. 2003 Mar 7;278(10):8460–8467.
   PubMed Web of Science ®Google Scholar
• Ramos FJ, Langlais PR, Hu D, et al. Grb10 mediates insulin-stimulated degradation of the insulin receptor: a mechanism of negative regulation. Am J Physiol Endocrinol Metab. 2006 Jun;290(6):E1262–6.
   PubMed Web of Science ®Google Scholar
• Yu Y, Yoon SO, Poulogiannis G, et al. Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science. 2011 Jun 10;332(6035):1322–1326.
   PubMed Web of Science ®Google Scholar
• Kasus-Jacobi A, Perdereau D, Auzan C, et al. Identification of the rat adapter Grb14 as an inhibitor of insulin actions. J Biol Chem. 1998 Oct 2;273(40):26026–26035.
   PubMed Web of Science ®Google Scholar
• Goenaga D, Hampe C, Carré N, et al. Molecular determinants of Grb14-mediated inhibition of insulin signaling. Mol endocrinol (Baltimore, Md). 2009;23(7):1043–1051.
   PubMedGoogle Scholar
• Perdereau D, Cailliau K, Browaeys-Poly E, et al. Insulin-induced cell division is controlled by the adaptor Grb14 in a Chfr-dependent manner. Cell Signal. 2015 Apr;27(4):798–806.
   PubMed Web of Science ®Google Scholar
• Pronk GJ, McGlade J, Pelicci G, et al. Insulin-induced phosphorylation of the 46- and 52-kDa Shc proteins. J Biol Chem. 1993 Mar 15;268(8):5748–5753.
   PubMed Web of Science ®Google Scholar
• Harmer SL, DeFranco AL. Shc contains two Grb2 binding sites needed for efficient formation of complexes with SOS in B lymphocytes. Mol Cell Biol. 1997;17(7):4087–4095.
   PubMed Web of Science ®Google Scholar
• Collins LR, Ricketts WA, Yeh L, et al. Bifurcation of cell migratory and proliferative signaling by the adaptor protein Shc. J Cell Biol. 1999 Dec 27;147(7):1561–1568.
   PubMed Web of Science ®Google Scholar
• Xu Y, Guo DF, Davidson M, et al. Interaction of the adaptor protein Shc and the adhesion molecule cadherin. J Biol Chem. 1997 May 23;272(21):13463–13466.
   PubMed Web of Science ®Google Scholar
• Bandaru P, Kondo Y, Kuriyan J. The Interdependent Activation of Son-of-Sevenless and Ras. Cold Spring Harb Perspect Med. 2019 Feb 1;9(2):a031534.
   PubMed Web of Science ®Google Scholar
• Saha M, Carriere A, Cheerathodi M, et al. RSK phosphorylates SOS1 creating 14-3-3-docking sites and negatively regulating MAPK activation. Biochem J. 2012 Oct 1;447(1):159–166.
   PubMedGoogle Scholar
• Corbalan-Garcia S, Yang SS, Degenhardt KR, et al. Identification of the mitogen-activated protein kinase phosphorylation sites on human Sos1 that regulate interaction with Grb2. Mol Cell Biol. 1996 Oct;16(10):5674–5682.
   PubMed Web of Science ®Google Scholar
• Denley A, Kang S, Karst U, et al. Oncogenic signaling of class I PI3K isoforms. Oncogene. 2008 Apr 17;27(18):2561–2574.
   PubMed Web of Science ®Google Scholar
• Zhao JJ, Cheng H, Jia S, et al. The p110alpha isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation. Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16296–16300.
   PubMed Web of Science ®Google Scholar
• Fox M, Mott HR, Owen D. Class IA PI3K regulatory subunits: p110-independent roles and structures. Biochem Soc Trans. 2020;48(4):1397–1417.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Viciana P, Warne PH, Dhand R, et al. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature. 1994 Aug 18;370(6490):527–532.
   PubMed Web of Science ®Google Scholar
• Madsen RR, Vanhaesebroeck B, Semple RK. Cancer-Associated PIK3CA Mutations in Overgrowth Disorders. Trends Mol Med. 2018 Oct;24(10):856–870.
   PubMed Web of Science ®Google Scholar
• Lawlor MA, Mora A, Ashby PR, et al. Essential role of PDK1 in regulating cell size and development in mice. EMBO J. 2002;21(14):3728–3738.
   PubMed Web of Science ®Google Scholar
• Pullen N, Dennis PB, Andjelkovic M, et al. Phosphorylation and activation of p70s6k by PDK1. Science. 1998 Jan 30;279(5351):707–710.
   PubMed Web of Science ®Google Scholar
• Dutil EM, Toker A, Newton AC. Regulation of conventional protein kinase C isozymes by phosphoinositide-dependent kinase 1 (PDK-1). Curr Biol. 1998 Dec 17-31;8(25):1366–1375.
   PubMed Web of Science ®Google Scholar
• Castel P, Ellis H, Bago R, et al. PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kalpha Inhibition. Cancer cell. 2016 Aug 8;30(2):229–242.
   PubMed Web of Science ®Google Scholar
• Scortegagna M, Lau E, Zhang T, et al. PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets. Cancer Res. 2015;75(7):1399–1412.
   PubMed Web of Science ®Google Scholar
• Manning BD, Toker A. AKT/PKB Signaling: Navigating the Network. Cell. 2017 Apr 20;169(3):381–405.
   PubMed Web of Science ®Google Scholar
• Sarbassov DD, Guertin DA, Ali SM, et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005 Feb 18;307(5712):1098–1101.
   PubMed Web of Science ®Google Scholar
• Moon Z, Wang Y, Aryan N, et al. Serine 396 of PDK1 is required for maximal PKB activation. Cell Signal. 2008 Nov;20(11):2038–2049.
   PubMed Web of Science ®Google Scholar
• Bellacosa A, Chan TO, Ahmed NN, et al. Akt activation by growth factors is a multiple-step process: the role of the PH domain. Oncogene. 1998 Jul 23;17(3):313–325.
   PubMed Web of Science ®Google Scholar
• Frias MA, Thoreen CC, Jaffe JD, et al. mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr Biol. 2006 Sep 19;16(18):1865–1870.
   PubMed Web of Science ®Google Scholar
• Fan Q, Wang Q, Cai R, et al. The ubiquitin system: orchestrating cellular signals in non-small-cell lung cancer. Cell Mol Biol Lett. 2020;25(1):1.
   PubMed Web of Science ®Google Scholar
• Gonzalez E, McGraw TE. Insulin-modulated Akt subcellular localization determines Akt isoform-specific signaling. Proc Natl Acad Sci U S A. 2009 Apr 28;106(17):7004–7009.
   PubMed Web of Science ®Google Scholar
• Nguyen le XT, Mitchell BS. Akt activation enhances ribosomal RNA synthesis through casein kinase II and TIF-IA. Proc Natl Acad Sci U S A. 2013 Dec 17;110(51):20681–20686.
   PubMed Web of Science ®Google Scholar
• Chen K, Jiao X, Di Rocco A, et al. Endogenous Cyclin D1 Promotes the Rate of Onset and Magnitude of Mitogenic Signaling via Akt1 Ser473 Phosphorylation. Cell Rep. 2020 Sep 15;32(11):108151.
   PubMed Web of Science ®Google Scholar
• Cristofano AD, Pesce B, Cordon-Cardo C, et al. Pten is essential for embryonic development and tumour suppression. Nat Genet. 1998 Aug 01;19(4):348–355.
   PubMed Web of Science ®Google Scholar
• Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol. 2012 May 01;13(5):283–296.
   PubMed Web of Science ®Google Scholar
• Nguyen KT, Tajmir P, Lin CH, et al. Essential role of Pten in body size determination and pancreatic beta-cell homeostasis in vivo. Mol Cell Biol. 2006 Jun;26(12):4511–4518.
   PubMed Web of Science ®Google Scholar
• Myers MP, Pass I, Batty IH, et al. The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13513–13518.
   PubMed Web of Science ®Google Scholar
• Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem. 1998 May 29;273(22):13375–13378.
   PubMed Web of Science ®Google Scholar
• Al-Khouri AM, Ma Y, Togo SH, et al. Cooperative phosphorylation of the tumor suppressor phosphatase and tensin homologue (PTEN) by casein kinases and glycogen synthase kinase 3beta. J Biol Chem. 2005 Oct 21;280(42):35195–35202.
   PubMed Web of Science ®Google Scholar
• Lee YR, Chen M, Lee JD, et al. Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathway. Science. 2019 May 17;364(6441). DOI:10.1126/science.aau0159
   Web of Science ®Google Scholar
• Papa A, Wan L, Bonora M, et al. Cancer-associated PTEN mutants act in a dominant-negative manner to suppress PTEN protein function. Cell. 2014;157(3):595–610.
   PubMed Web of Science ®Google Scholar
• Saxton RA, Sabatini DM. mTOR Signaling in Growth, Metabolism, and Disease. Cell. 2017 Mar 9;168(6):960–976.
   PubMed Web of Science ®Google Scholar
• Cai SL, Tee AR, Short JD, et al. Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning. J Cell Biol. 2006 Apr 24;173(2):279–289.
   PubMed Web of Science ®Google Scholar
• Garami A, Zwartkruis FJ, Nobukuni T, et al. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol Cell. 2003 Jun;11(6):1457–1466.
   PubMed Web of Science ®Google Scholar
• Manning BD, Tee AR, Logsdon MN, et al. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell. 2002 Jul;10(1):151–162.
   PubMed Web of Science ®Google Scholar
• Long X, Lin Y, Ortiz-Vega S, et al. Rheb binds and regulates the mTOR kinase. Curr Biol. 2005 Apr 26;15(8):702–713.
   PubMed Web of Science ®Google Scholar
• Hanrahan J, Blenis J. Rheb activation of mTOR and S6K1 signaling. Methods Enzymol. 2006;407:542–555.
   PubMed Web of Science ®Google Scholar
• Gao X, Pan D. TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth. Genes Dev. 2001 Jun 1;15(11):1383–1392.
   PubMed Web of Science ®Google Scholar
• Roux PP, Ballif BA, Anjum R, et al. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc Natl Acad Sci U S A. 2004 Sep 14;101(37):13489–13494.
   PubMed Web of Science ®Google Scholar
• Ma L, Chen Z, Erdjument-Bromage H, et al. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell. 2005 Apr 22;121(2):179–193.
   PubMed Web of Science ®Google Scholar
• Rosner M, Hofer K, Kubista M, et al. Cell size regulation by the human TSC tumor suppressor proteins depends on PI3K and FKBP38. Oncogene. 2003 Jul 31;22(31):4786–4798.
   PubMed Web of Science ®Google Scholar
• Scott PH, Brunn GJ, Kohn AD, et al. Evidence of insulin-stimulated phosphorylation and activation of the mammalian target of rapamycin mediated by a protein kinase B signaling pathway. Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7772–7777.
   PubMed Web of Science ®Google Scholar
• Guertin DA, Stevens DM, Thoreen CC, et al. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell. 2006 Dec;11(6):859–871.
   PubMed Web of Science ®Google Scholar
• Kim DH, Sarbassov DD, Ali SM, et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell. 2002 Jul 26;110(2):163–175.
   PubMed Web of Science ®Google Scholar
• Jacinto E, Facchinetti V, Liu D, et al. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell. 2006 Oct 6;127(1):125–137.
   PubMed Web of Science ®Google Scholar
• Avruch J, Hara K, Lin Y, et al. Insulin and amino-acid regulation of mTOR signaling and kinase activity through the Rheb GTPase. Oncogene. 2006 Oct 16;25(48):6361–6372.
   PubMed Web of Science ®Google Scholar
• Holz MK, Blenis J. Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase. J Biol Chem. 2005 Jul 15;280(28):26089–26093.
   PubMed Web of Science ®Google Scholar
• Holz MK, Ballif BA, Gygi SP, et al. mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell. 2005 Nov 18;123(4):569–580.
   PubMed Web of Science ®Google Scholar
• Sabatini DM, Erdjument-Bromage H, Lui M, et al. RAFT1: A mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell. 1994 July 15;78(1):35–43.
   PubMed Web of Science ®Google Scholar
• Yang H, Jiang X, Li B, et al. Mechanisms of mTORC1 activation by RHEB and inhibition by PRAS40. Nature. 2017;552(7685):368–373.
   PubMed Web of Science ®Google Scholar
• Jacinto E, Loewith R, Schmidt A, et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol. 2004 Nov;6(11):1122–1128.
   PubMed Web of Science ®Google Scholar
• Sarbassov DD, Ali SM, Kim DH, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol. 2004 Jul 27;14(14):1296–1302.
   PubMed Web of Science ®Google Scholar
• Sarbassov DD, Ali SM, Sengupta S, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell. 2006 Apr 21;22(2):159–168.
   PubMed Web of Science ®Google Scholar
• Chou PC, Rajput S, Zhao X, et al. mTORC2 Is Involved in the Induction of RSK Phosphorylation by Serum or Nutrient Starvation. Cells. 2020 Jun 27;9(7):1567.
   PubMed Web of Science ®Google Scholar
• Li X, Gao T. mTORC2 phosphorylates protein kinase Cζ to regulate its stability and activity. EMBO Rep. 2014 Feb;15(2):191–198.
   PubMed Web of Science ®Google Scholar
• Baffi TR, Lordén G, Wozniak JM, et al. mTORC2 controls the activity of PKC and Akt by phosphorylating a conserved TOR interaction motif. Sci Signal. 2021;14(678):eabe4509.
   PubMed Web of Science ®Google Scholar
• Briaud I, Dickson LM, Lingohr MK, et al. Insulin receptor substrate-2 proteasomal degradation mediated by a mammalian target of rapamycin (mTOR)-induced negative feedback down-regulates protein kinase B-mediated signaling pathway in beta-cells. J Biol Chem. 2005 Jan 21;280(3):2282–2293.
   PubMed Web of Science ®Google Scholar
• Rodrik-Outmezguine VS, Chandarlapaty S, Pagano NC, et al. mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discov. 2011 Aug;1(3):248–259.
   PubMed Web of Science ®Google Scholar
• Carracedo A, Ma L, Teruya-Feldstein J, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest. 2008 Sep;118(9):3065–3074.
   PubMed Web of Science ®Google Scholar
• Kinkade CW, Castillo-Martin M, Puzio-Kuter A, et al. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest. 2008 Sep;118(9):3051–3064.
   PubMed Web of Science ®Google Scholar
• Sridharan S, Basu A. Distinct Roles of mTOR Targets S6K1 and S6K2 in Breast Cancer. Int J Mol Sci. 2020;21(4):1199.
   PubMed Web of Science ®Google Scholar
• Shima H, Pende M, Chen Y, et al. Disruption of the p70(s6k)/p85(s6k) gene reveals a small mouse phenotype and a new functional S6 kinase. EMBO J. 1998 Nov 16;17(22):6649–6659.
   PubMed Web of Science ®Google Scholar
• Gentilella A, Kozma SC, Thomas G. A liaison between mTOR signaling, ribosome biogenesis and cancer. Biochim Biophys Acta. 2015 Jul;1849(7):812–820.
   PubMed Web of Science ®Google Scholar
• Liu GY, Sabatini DM. mTOR at the nexus of nutrition, growth, ageing and disease. Nat Rev Mol Cell Biol. 2020 Apr 01;21(4):183–203.
   PubMed Web of Science ®Google Scholar
• Ben-Hur V, Denichenko P, Siegfried Z, et al. S6K1 alternative splicing modulates its oncogenic activity and regulates mTORC1. Cell Rep. 2013 Jan 31;3(1):103–115.
   PubMed Web of Science ®Google Scholar
• Ben-Sahra I, Manning BD. mTORC1 signaling and the metabolic control of cell growth. Curr Opin Cell Biol. 2017 Apr;45:72–82.
   PubMed Web of Science ®Google Scholar
• Szwed A, Kim E, Jacinto E. Regulation and metabolic functions of mTORC1 and mTORC2. Physiol Rev. 2021 Jul 1;101(3):1371–1426.
   PubMed Web of Science ®Google Scholar
• Dibble CC, Asara JM, Manning BD. Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1. Mol Cell Biol. 2009 Nov;29(21):5657–5670.
   PubMed Web of Science ®Google Scholar
• Liu P, Gan W, Inuzuka H, et al. Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis. Nat Cell Biol. 2013 Nov;15(11):1340–1350.
   PubMed Web of Science ®Google Scholar
• Julien L-A, Carriere A, Moreau J, et al. mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling. Mol Cell Biol. 2010;30(4):908–921.
   PubMed Web of Science ®Google Scholar
• Chauvin C, Koka V, Nouschi A, et al. Ribosomal protein S6 kinase activity controls the ribosome biogenesis transcriptional program. Oncogene. 2014 Jan 23;33(4):474–483.
   PubMed Web of Science ®Google Scholar
• Rosner M, Hengstschlager M. Nucleocytoplasmic localization of p70 S6K1, but not of its isoforms p85 and p31, is regulated by TSC2/mTOR. Oncogene. 2011 Nov 3;30(44):4509–4522.
   PubMed Web of Science ®Google Scholar
• Martineau Y, Azar R, Bousquet C, et al. Anti-oncogenic potential of the eIF4E-binding proteins. Oncogene. 2013 Feb 7;32(6):671–677.
   PubMed Web of Science ®Google Scholar
• Muller D, Lasfargues C, El Khawand S, et al. 4E-BP restrains eIF4E phosphorylation. Translation (Austin). 2013;1(2):e25819.
   PubMedGoogle Scholar
• Mendez R, Myers MG Jr., White MF, et al. Stimulation of protein synthesis, eukaryotic translation initiation factor 4E phosphorylation, and PHAS-I phosphorylation by insulin requires insulin receptor substrate 1 and phosphatidylinositol 3-kinase. Mol Cell Biol. 1996 Jun;16(6):2857–2864.
   PubMed Web of Science ®Google Scholar
• Wang X, Proud CG. The mTOR pathway in the control of protein synthesis. Physiology (Bethesda). 2006 Oct;21:362–369.
   PubMed Web of Science ®Google Scholar
• Sukarieh R, Sonenberg N, Pelletier J. The eIF4E-binding proteins are modifiers of cytoplasmic eIF4E relocalization during the heat shock response. Am J Physiol Cell Physiol. 2009 May;296(5):C1207–17.
   PubMed Web of Science ®Google Scholar
• Culjkovic-Kraljacic B, Skrabanek L, Revuelta MV, et al. The eukaryotic translation initiation factor eIF4E elevates steady-state m(7)G capping of coding and noncoding transcripts. Proc Natl Acad Sci U S A. 2020 Oct 27;117(43):26773–26783.
   PubMed Web of Science ®Google Scholar
• Llanos S, Garcia-Pedrero JM, Morgado-Palacin L, et al. Stabilization of p21 by mTORC1/4E-BP1 predicts clinical outcome of head and neck cancers. Nat Commun. 2016 Feb 2;7(1):10438.
   PubMedGoogle Scholar
• Jiang H, Coleman J, Miskimins R, et al. Expression of constitutively active 4EBP-1 enhances p27Kip1 expression and inhibits proliferation of MCF7 breast cancer cells. Cancer Cell Int. 2003 Feb 18;3(1):2.
   PubMedGoogle Scholar
• Tsukiyama-Kohara K, Poulin F, Kohara M, et al. Adipose tissue reduction in mice lacking the translational inhibitor 4E-BP1. Nat Med. 2001 Oct 01;7(10):1128–1132.
   PubMed Web of Science ®Google Scholar
• Teleman AA, Chen Y-W, Cohen SM. 4E-BP functions as a metabolic brake used under stress conditions but not during normal growth. Genes Dev. 2005;19(16):1844–1848.
   PubMed Web of Science ®Google Scholar
• Maurer U, Preiss F, Brauns-Schubert P, et al. GSK-3 – at the crossroads of cell death and survival. J Cell Sci. 2014;127(7):1369–1378.
   PubMed Web of Science ®Google Scholar
• Mora A, Sakamoto K, McManus EJ, et al. Role of the PDK1-PKB-GSK3 pathway in regulating glycogen synthase and glucose uptake in the heart. FEBS Lett. 2005 Jul 4;579(17):3632–3638.
   PubMed Web of Science ®Google Scholar
• Shaw M, Cohen P, Alessi DR. Further evidence that the inhibition of glycogen synthase kinase-3β by IGF-1 is mediated by PDK1/PKB-induced phosphorylation of Ser-9 and not by dephosphorylation of Tyr-216. FEBS Lett. 1997;416(3):307–311.
   PubMed Web of Science ®Google Scholar
• Welsh GI, Proud CG. Glycogen synthase kinase-3 is rapidly inactivated in response to insulin and phosphorylates eukaryotic initiation factor eIF-2B. Biochem J. 1993;294(Pt 3):625–629.
   PubMedGoogle Scholar
• Sung CK, Choi WS, Scalia P. Insulin-stimulated glycogen synthesis in cultured hepatoma cells: differential effects of inhibitors of insulin signaling molecules. J Recept Signal Transduct Res. 1998 Jul-Nov;18(4–6):243–263.
   PubMed Web of Science ®Google Scholar
• Welcker M, Orian A, Jin J, et al. The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc Natl Acad Sci U S A. 2004;101(24):9085–9090.
   PubMed Web of Science ®Google Scholar
• Diehl JA, Cheng M, Roussel MF, et al. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 1998 Nov 15;12(22):3499–3511.
   PubMed Web of Science ®Google Scholar
• Goode N, Hughes K, Woodgett JR, et al. Differential regulation of glycogen synthase kinase-3 beta by protein kinase C isotypes. J Biol Chem. 1992 Aug 25;267(24):16878–16882.
   PubMed Web of Science ®Google Scholar
• Jope RS, Johnson GV. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci. 2004 Feb;29(2):95–102.
   PubMed Web of Science ®Google Scholar
• Tanabe K, Liu Z, Patel S, et al. Genetic deficiency of glycogen synthase kinase-3beta corrects diabetes in mouse models of insulin resistance. PLoS Biol. 2008 Feb;6(2):e37.
   PubMed Web of Science ®Google Scholar
• Fernández-Medarde A, Santos E. Ras in cancer and developmental diseases. Genes Cancer. 2011;2(3):344–358.
   PubMedGoogle Scholar
• Prior IA, Hood FE, Hartley JL. The Frequency of Ras Mutations in Cancer. Cancer Res. 2020;80(14):2969–2974.
   PubMed Web of Science ®Google Scholar
• Kasid A, Lippman ME. Estrogen and oncogene mediated growth regulation of human breast cancer cells. J Steroid Biochem. 1987;27(1–3):465–470.
   PubMedGoogle Scholar
• Sell C, Dumenil G, Deveaud C, et al. Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Mol Cell Biol. 1994 Jun;14(6):3604–3612.
   PubMed Web of Science ®Google Scholar
• Harvey JJ. An Unidentified Virus Which Causes the Rapid Production of Tumours in Mice. Nature. 1964 Dec 12;204(4963):1104–1105.
   PubMedGoogle Scholar
• Hancock JF, Magee AI, Childs JE, et al. All ras proteins are polyisoprenylated but only some are palmitoylated. Cell. 1989 Jun 30;57(7):1167–1177.
   PubMed Web of Science ®Google Scholar
• Hancock JF, Cadwallader K, Paterson H, et al. A CAAX or a CAAL motif and a second signal are sufficient for plasma membrane targeting of ras proteins. EMBO J. 1991 Dec;10(13):4033–4039.
   PubMed Web of Science ®Google Scholar
• Hancock JF, Cadwallader K, Marshall CJ. Methylation and proteolysis are essential for efficient membrane binding of prenylated p21K-ras(B). EMBO J. 1991 Mar;10(3):641–646.
   PubMed Web of Science ®Google Scholar
• McKay MM, Morrison DK. Integrating signals from RTKs to ERK/MAPK. Oncogene. 2007 May 14;26(22):3113–3121.
   PubMed Web of Science ®Google Scholar
• Arvidsson AK, Rupp E, Nånberg E, et al. Tyr-716 in the platelet-derived growth factor beta-receptor kinase insert is involved in GRB2 binding and Ras activation. Mol Cell Biol. 1994;14(10):6715–6726.
   PubMed Web of Science ®Google Scholar
• Kovalski JR, Bhaduri A, Zehnder AM, et al. The Functional Proximal Proteome of Oncogenic Ras Includes mTORC2. Mol Cell. 2019 Feb 21;73(4):830–844 e12.
   PubMed Web of Science ®Google Scholar
• Gillies TE, Pargett M, Silva JM, et al. Oncogenic mutant RAS signaling activity is rescaled by the ERK/MAPK pathway. Mol Syst Biol. 2020 Oct;16(10):e9518.
   PubMed Web of Science ®Google Scholar
• Nakamura K, Ichise H, Nakao K, et al. Partial functional overlap of the three ras genes in mouse embryonic development. Oncogene. 2008 May 8;27(21):2961–2968.
   PubMed Web of Science ®Google Scholar
• Johnson L, Greenbaum D, Cichowski K, et al. K-ras is an essential gene in the mouse with partial functional overlap with N-ras. Genes Dev. 1997 Oct 1;11(19):2468–2481.
   PubMed Web of Science ®Google Scholar
• Niault TS, Baccarini M. Targets of Raf in tumorigenesis. Carcinogenesis. 2010 Jul;31(7):1165–1174.
   PubMed Web of Science ®Google Scholar
• Tran TH, Chan AH, Young LC, et al. KRAS interaction with RAF1 RAS-binding domain and cysteine-rich domain provides insights into RAS-mediated RAF activation. Nat Commun. 2021 Feb 19;12(1):1176.
   PubMed Web of Science ®Google Scholar
• Hmitou I, Druillennec S, Valluet A, et al. Differential regulation of B-raf isoforms by phosphorylation and autoinhibitory mechanisms. Mol Cell Biol. 2007 Jan;27(1):31–43.
   PubMed Web of Science ®Google Scholar
• Galabova-Kovacs G, Kolbus A, Matzen D, et al. ERK and beyond: insights from B-Raf and Raf-1 conditional knockouts. Cell Cycle. 2006 Jul;5(14):1514–1518.
   PubMed Web of Science ®Google Scholar
• Martinez Fiesco JA, Durrant DE, Morrison DK, et al. Structural insights into the BRAF monomer-to-dimer transition mediated by RAS binding. Nat Commun. 2022 Jan 25;13(1):486.
   PubMed Web of Science ®Google Scholar
• Wojnowski L, Stancato LF, Zimmer AM, et al. Craf-1 protein kinase is essential for mouse development. Mech Dev. 1998 Aug;76(1–2):141–149.
   PubMed Web of Science ®Google Scholar
• Hüser M, Luckett J, Chiloeches A, et al. MEK kinase activity is not necessary for Raf-1 function. EMBO J. 2001;20(8):1940–1951.
   PubMed Web of Science ®Google Scholar
• Mercer K, Giblett S, Oakden A, et al. A-Raf and Raf-1 work together to influence transient ERK phosphorylation and Gl/S cell cycle progression. Oncogene. 2005 Aug 4;24(33):5207–5217.
   PubMed Web of Science ®Google Scholar
• Venkatanarayan A, Liang J, Yen I, et al. CRAF dimerization with ARAF regulates KRAS-driven tumor growth. Cell Rep. 2022 Feb 08;38(6):110351.
   PubMed Web of Science ®Google Scholar
• Eblen ST, Slack-Davis JK, Tarcsafalvi A, et al. Mitogen-activated protein kinase feedback phosphorylation regulates MEK1 complex formation and activation during cellular adhesion. Mol Cell Biol. 2004 Mar;24(6):2308–2317.
   PubMed Web of Science ®Google Scholar
• Brady SC, Coleman ML, Munro J, et al. Sprouty2 association with B-Raf is regulated by phosphorylation and kinase conformation. Cancer Res. 2009 Sep 1;69(17):6773–6781.
   PubMed Web of Science ®Google Scholar
• Pratilas CA, Taylor BS, Ye Q, et al. (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4519–4524.
   PubMed Web of Science ®Google Scholar
• Scalia P, Williams SJ, Ventura E, et al. The Onco-genomic Landscape of Malignant Melanoma: The Tumor Microenvironment comes of Age. J Cancer Res Clin Oncol. 2020;3(1):1–8.
   Google Scholar
• Alessi DR, Saito Y, Campbell DG, et al. Identification of the sites in MAP kinase kinase-1 phosphorylated by p74raf-1. EMBO J. 1994;13(7):1610–1619.
   PubMed Web of Science ®Google Scholar
• Schaeffer HJ, Catling AD, Eblen ST, et al. MP1: a MEK binding partner that enhances enzymatic activation of the MAP kinase cascade. Science. 1998 Sep 11;281(5383):1668–1671.
   PubMed Web of Science ®Google Scholar
• Teis D, Wunderlich W, Huber LA. Localization of the MP1-MAPK scaffold complex to endosomes is mediated by p14 and required for signal transduction. Dev Cell. 2002 Dec;3(6):803–814.
   PubMed Web of Science ®Google Scholar
• Procaccia S, Ordan M, Cohen I, et al. Direct binding of MEK1 and MEK2 to AKT induces Foxo1 phosphorylation, cellular migration and metastasis. Sci Rep. 2017 Feb 22;7(1):43078.
   PubMedGoogle Scholar
• Giroux S, Tremblay M, Bernard D, et al. Embryonic death of Mek1-deficient mice reveals a role for this kinase in angiogenesis in the labyrinthine region of the placenta. Curr Biol. 1999 Apr 8;9(7):369–372.
   PubMed Web of Science ®Google Scholar
• Bélanger L-F, Roy S, Tremblay M, et al. Mek2 is dispensable for mouse growth and development. Mol Cell Biol. 2003;23(14):4778–4787.
   PubMed Web of Science ®Google Scholar
• Sturgill TW, Ray LB, Erikson E, et al. Insulin-stimulated MAP-2 kinase phosphorylates and activates ribosomal protein S6 kinase II. Nature. 1988 Aug 25;334(6184):715–718.
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Ebisuya M, Ashida F, et al. Continuous ERK activation downregulates antiproliferative genes throughout G1 phase to allow cell-cycle progression. Curr Biol. 2006 Jun 20;16(12):1171–1182.
   PubMed Web of Science ®Google Scholar
• Eblen ST. Extracellular-Regulated Kinases: Signaling From Ras to ERK Substrates to Control Biological Outcomes. Adv Cancer Res. 2018;138:99–142.
   PubMed Web of Science ®Google Scholar
• Schmidt M, Fernandez de Mattos S, van der Horst A, et al. Cell cycle inhibition by FoxO forkhead transcription factors involves downregulation of cyclin D. Mol Cell Biol. 2002 Nov;22(22):7842–7852.
   PubMed Web of Science ®Google Scholar
• Dijkers PF, Medema RH, Pals C, et al. Forkhead transcription factor FKHR-L1 modulates cytokine-dependent transcriptional regulation of p27(KIP1). Mol Cell Biol. 2000 Dec;20(24):9138–9148.
   PubMed Web of Science ®Google Scholar
• Yang JY, Zong CS, Xia W, et al. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol. 2008 Feb;10(2):138–148.
   PubMed Web of Science ®Google Scholar
• Brunet A, Pages G, Pouyssegur J. Constitutively active mutants of MAP kinase kinase (MEK1) induce growth factor-relaxation and oncogenicity when expressed in fibroblasts. Oncogene. 1994 Nov;9(11):3379–3387.
   PubMed Web of Science ®Google Scholar
• Mansour SJ, Matten WT, Hermann AS, et al. Transformation of mammalian cells by constitutively active MAP kinase kinase. Science. 1994 Aug 12;265(5174):966–970.
   PubMed Web of Science ®Google Scholar
• Brummer T, Naegele H, Reth M, et al. Identification of novel ERK-mediated feedback phosphorylation sites at the C-terminus of B-Raf. Oncogene. 2003 Dec 4;22(55):8823–8834.
   PubMed Web of Science ®Google Scholar
• Ritt DA, Monson DM, Specht SI, et al. Impact of feedback phosphorylation and Raf heterodimerization on normal and mutant B-Raf signaling. Mol Cell Biol. 2010 Feb;30(3):806–819.
   PubMed Web of Science ®Google Scholar
• Rozakis-Adcock M, van der Geer P, Mbamalu G, et al. MAP kinase phosphorylation of mSos1 promotes dissociation of mSos1-Shc and mSos1-EGF receptor complexes. Oncogene. 1995 Oct 5;11(7):1417–1426.
   PubMed Web of Science ®Google Scholar
• Fritsche L, Neukamm SS, Lehmann R, et al. Insulin-induced serine phosphorylation of IRS-2 via ERK1/2 and mTOR: studies on the function of Ser675 and Ser907. Am J Physiol Endocrinol Metab. 2011 May;300(5):E824–36.
   PubMed Web of Science ®Google Scholar
• Furuta H, Yoshihara H, Fukushima T, et al. IRS-2 deubiquitination by USP9X maintains anchorage-independent cell growth via Erk1/2 activation in prostate carcinoma cell line. Oncotarget. 2018 Sep 21;9(74):33871–33883.
   PubMedGoogle Scholar
• Saba-El-Leil MK, Vella FDJ, Vernay B, et al. An essential function of the mitogen-activated protein kinase Erk2 in mouse trophoblast development. EMBO Rep. 2003;4(10):964–968.
   PubMed Web of Science ®Google Scholar
• Pages G, Guerin S, Grall D, et al. Defective thymocyte maturation in p44 MAP kinase (Erk 1) knockout mice. Science. 1999 Nov 12;286(5443):1374–1377.
   PubMed Web of Science ®Google Scholar
• Bruning JC, Gillette JA, Zhao Y, et al. Ribosomal subunit kinase-2 is required for growth factor-stimulated transcription of the c-Fos gene. Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2462–2467.
   PubMed Web of Science ®Google Scholar
• Erikson RL. Regulation of cell proliferation by oncogene products and growth factors. Somat Cell Mol Genet. 1987 Jul;13(4):459–461.
   PubMedGoogle Scholar
• Lara R, Seckl MJ, Pardo OE. The p90 RSK family members: common functions and isoform specificity. Cancer Res. 2013 Sep 1;73(17):5301–5308.
   PubMed Web of Science ®Google Scholar
• Fujita N, Sato S, Tsuruo T. Phosphorylation of p27Kip1 at threonine 198 by p90 ribosomal protein S6 kinases promotes its binding to 14-3-3 and cytoplasmic localization. J Biol Chem. 2003 Dec 5;278(49):49254–49260.
   PubMed Web of Science ®Google Scholar
• Chen RH, Abate C, Blenis J. Phosphorylation of the c-Fos transrepression domain by mitogen-activated protein kinase and 90-kDa ribosomal S6 kinase. Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):10952–10956.
   PubMed Web of Science ®Google Scholar
• Torres MA, Eldar-Finkelman H, Krebs EG, et al. Regulation of ribosomal S6 protein kinase-p90(rsk), glycogen synthase kinase 3, and beta-catenin in early Xenopus development. Mol Cell Biol. 1999 Feb;19(2):1427–1437.
   PubMed Web of Science ®Google Scholar
• Douville E, Downward J. EGF induced SOS phosphorylation in PC12 cells involves P90 RSK-2. Oncogene. 1997 Jul 24;15(4):373–383.
   PubMed Web of Science ®Google Scholar
• De S, Campbell C, Venkitaraman AR, et al. Pulsatile MAPK Signaling Modulates p53 Activity to Control Cell Fate Decisions at the G2 Checkpoint for DNA Damage. Cell Rep. 2020;30(7):2083–2093.e5.
   PubMed Web of Science ®Google Scholar
• Albeck JG, Mills GB, Brugge JS. Frequency-modulated pulses of ERK activity transmit quantitative proliferation signals. Mol Cell. 2013 Jan 24;49(2):249–261.
   PubMed Web of Science ®Google Scholar
• Dufresne SD, Bjorbaek C, El-Haschimi K, et al. Altered extracellular signal-regulated kinase signaling and glycogen metabolism in skeletal muscle from p90 ribosomal S6 kinase 2 knockout mice. Mol Cell Biol. 2001 Jan;21(1):81–87.
   PubMed Web of Science ®Google Scholar
• Kops GJ, Medema RH, Glassford J, et al. Control of cell cycle exit and entry by protein kinase B-regulated forkhead transcription factors. Mol Cell Biol. 2002 Apr;22(7):2025–2036.
   PubMed Web of Science ®Google Scholar
• Puig O, Tjian R. Transcriptional feedback control of insulin receptor by dFOXO/FOXO1. Genes Dev. 2005 Oct 15;19(20):2435–2446.
   PubMed Web of Science ®Google Scholar
• Essaghir A, Dif N, Marbehant CY, et al. The transcription of FOXO genes is stimulated by FOXO3 and repressed by growth factors. J Biol Chem. 2009;284(16):10334–10342.
   PubMed Web of Science ®Google Scholar
• Sang T, Cao Q, Wang Y, et al. Overexpression or silencing of FOXO3a affects proliferation of endothelial progenitor cells and expression of cell cycle regulatory proteins. PloS one. 2014;9(8):e101703–e101703.
   PubMed Web of Science ®Google Scholar
• Demontis F, Perrimon N. Integration of Insulin receptor/Foxo signaling and dMyc activity during muscle growth regulates body size in Drosophila. Development. 2009 Mar;136(6):983–993.
   PubMed Web of Science ®Google Scholar
• Junger MA, Rintelen F, Stocker H, et al. The Drosophila forkhead transcription factor FOXO mediates the reduction in cell number associated with reduced insulin signaling. J Biol. 2003;2(3):20.
   PubMedGoogle Scholar
• Murphy LO, MacKeigan JP, Blenis J. A network of immediate early gene products propagates subtle differences in mitogen-activated protein kinase signal amplitude and duration. Mol Cell Biol. 2004 Jan;24(1):144–153.
   PubMed Web of Science ®Google Scholar
• Karin M. The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem. 1995 Jul 14;270(28):16483–16486.
   PubMed Web of Science ®Google Scholar
• Koo JH, Plouffe SW, Meng Z, et al. Induction of AP-1 by YAP/TAZ contributes to cell proliferation and organ growth. Genes Dev. 2020 Jan 1;34(1–2):72–86.
   PubMed Web of Science ®Google Scholar
• Berberich SJ, Cole MD. Casein kinase II inhibits the DNA-binding activity of Max homodimers but not Myc/Max heterodimers. Genes Dev. 1992 Feb;6(2):166–176.
   PubMed Web of Science ®Google Scholar
• Zhu J, Blenis J, Yuan J. Activation of PI3K/Akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1. Proc Natl Acad Sci U S A. 2008 May 6;105(18):6584–6589.
   PubMed Web of Science ®Google Scholar
• Garcia-Gutierrez L, Delgado MD, Leon J. MYC Oncogene Contributions to Release of Cell Cycle Brakes. Genes (Basel). 2019 Mar 22;10(3):244.
   PubMed Web of Science ®Google Scholar
• Vlach J, Hennecke S, Alevizopoulos K, et al. Growth arrest by the cyclin-dependent kinase inhibitor p27Kip1 is abrogated by c-Myc. EMBO J. 1996;15(23):6595–6604.
   PubMed Web of Science ®Google Scholar
• Zou Z, Chen J, Liu A, et al. mTORC2 promotes cell survival through c-Myc-dependent up-regulation of E2F1. J Cell Biol. 2015 Oct 12;211(1):105–122.
   PubMed Web of Science ®Google Scholar
• Ohtani K, DeGregori J, Nevins JR. Regulation of the cyclin E gene by transcription factor E2F1. Proc Natl Acad Sci U S A. 1995 Dec 19;92(26):12146–12150.
   PubMed Web of Science ®Google Scholar
• Chandramohan V, Mineva ND, Burke B, et al. c-Myc represses FOXO3a-mediated transcription of the gene encoding the p27(Kip1) cyclin dependent kinase inhibitor. J Cell Biochem. 2008 Aug 15;104(6):2091–2106.
   PubMed Web of Science ®Google Scholar
• Morrish F, Neretti N, Sedivy JM, et al. The oncogene c-Myc coordinates regulation of metabolic networks to enable rapid cell cycle entry. Cell Cycle. 2008 Apr 15;7(8):1054–1066.
   PubMed Web of Science ®Google Scholar
• Grandori C, Gomez-Roman N, Felton-Edkins ZA, et al. c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I. Nat Cell Biol. 2005 Mar;7(3):311–318.
   PubMed Web of Science ®Google Scholar
• Krek W, Xu G, Livingston DM. Cyclin A-kinase regulation of E2F-1 DNA binding function underlies suppression of an S phase checkpoint. Cell. 1995 Dec 29;83(7):1149–1158.
   PubMed Web of Science ®Google Scholar
• Johnson DG, Schneider-Broussard R. Role of E2F in cell cycle control and cancer. Front Biosci. 1998 Apr 27;3(4):d447–8.
   PubMedGoogle Scholar
• Polager S, Ginsberg D. p53 and E2f: partners in life and death. Nat Rev Cancer. 2009 Oct;9(10):738–748.
   PubMed Web of Science ®Google Scholar
• Lin SY, Black AR, Kostic D, et al. Cell cycle-regulated association of E2F1 and Sp1 is related to their functional interaction. Mol Cell Biol. 1996 Apr;16(4):1668–1675.
   PubMed Web of Science ®Google Scholar
• Rosner HI, Sorensen CS. E2F transcription regulation: an orphan cyclin enters the stage. EMBO J. 2019 Oct 15;38(20):e103421.
   PubMed Web of Science ®Google Scholar
• Bae SK, Bae MH, Ahn MY, et al. Egr-1 mediates transcriptional activation of IGF-II gene in response to hypoxia. Cancer Res. 1999 Dec 1;59(23):5989–5994.
   PubMed Web of Science ®Google Scholar
• Ma Y, Cheng Q, Ren Z, et al. Induction of IGF-1R expression by EGR-1 facilitates the growth of prostate cancer cells. Cancer Lett. 2012 Apr 28;317(2):150–156.
   PubMed Web of Science ®Google Scholar
• Baron V, Adamson ED, Calogero A, et al. The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFbeta1, PTEN, p53, and fibronectin. Cancer Gene Ther. 2006 Feb;13(2):115–124.
   PubMed Web of Science ®Google Scholar
• Yu J, Zhang SS, Saito K, et al. PTEN regulation by Akt-EGR1-ARF-PTEN axis. EMBO J. 2009 Jan 7;28(1):21–33.
   PubMed Web of Science ®Google Scholar
• Hanke S, Mann M. The phosphotyrosine interactome of the insulin receptor family and its substrates IRS-1 and IRS-2. Mol Cell Proteomics. 2009 Mar;8(3):519–534.
   PubMed Web of Science ®Google Scholar
• Nurk S, Koren S, Rhie A, et al. The complete sequence of a human genome. Science. 2022 Apr;376(6588):44–53.
   PubMed Web of Science ®Google Scholar
• Pelletier J, Thomas G, Volarevic S. Ribosome biogenesis in cancer: new players and therapeutic avenues. Nat Rev Cancer. 2018 Jan;18(1):51–63.
   PubMed Web of Science ®Google Scholar
• Klein J, Grummt I. Cell cycle-dependent regulation of RNA polymerase I transcription: the nucleolar transcription factor UBF is inactive in mitosis and early G1. Proc Natl Acad Sci U S A. 1999 May 25;96(11):6096–6101.
   PubMed Web of Science ®Google Scholar
• White RJ, Gottlieb TM, Downes CS, et al. Cell cycle regulation of RNA polymerase III transcription. Mol Cell Biol. 1995 Dec;15(12):6653–6662.
   PubMed Web of Science ®Google Scholar
• Surmacz E, Kaczmarek L, Ronning O, et al. Activation of the ribosomal DNA promoter in cells exposed to insulinlike growth factor I. Mol Cell Biol. 1987 Feb;7(2):657–663.
   PubMed Web of Science ®Google Scholar
• Michels AA, Robitaille AM, Buczynski-Ruchonnet D, et al. mTORC1 directly phosphorylates and regulates human MAF1. Mol Cell Biol. 2010 Aug;30(15):3749–3757.
   PubMed Web of Science ®Google Scholar
• Rideout EJ, Marshall L, Grewal SS. Drosophila RNA polymerase III repressor Maf1 controls body size and developmental timing by modulating tRNAiMet synthesis and systemic insulin signaling. Proc Natl Acad Sci U S A. 2012 Jan 24;109(4):1139–1144.
   PubMed Web of Science ®Google Scholar
• DePhilip RM, Rudert WA, Lieberman I. Preferential stimulation of ribosomal protein synthesis by insulin and in the absence of ribosomal and messenger ribonucleic acid formation. Biochemistry. 1980 Apr 15;19(8):1662–1669.
   PubMed Web of Science ®Google Scholar
• Hammond ML, Bowman LH. Insulin stimulates the translation of ribosomal proteins and the transcription of rDNA in mouse myoblasts. J Biol Chem. 1988 Nov 25;263(33):17785–17791.
   PubMed Web of Science ®Google Scholar
• Scalia, P , Comai, L Regulation of Polymerase-I Transcription by Insulin-Like Growth Factor-II. Third International Symposium on Polymerase I & III. Craig SP ed. (Gene Expression (Cognizant Comm)). June 5-9. Asilomar Conference Grounds, Pacific Grove, Monterrey CA. 2002; Vol 10. 263–270.
   Google Scholar
• Lin CY, Navarro S, Reddy S, et al. CK2-mediated stimulation of Pol I transcription by stabilization of UBF-SL1 interaction. Nucleic Acids Res. 2006;34(17):4752–4766.
   PubMed Web of Science ®Google Scholar
• Bierhoff H, Dundr M, Michels AA, et al. Phosphorylation by casein kinase 2 facilitates rRNA gene transcription by promoting dissociation of TIF-IA from elongating RNA polymerase I. Mol Cell Biol. 2008 Aug;28(16):4988–4998.
   PubMed Web of Science ®Google Scholar
• Zhao J, Yuan X, Frodin M, et al. ERK-dependent phosphorylation of the transcription initiation factor TIF-IA is required for RNA polymerase I transcription and cell growth. Mol Cell. 2003 Feb;11(2):405–413.
   PubMed Web of Science ®Google Scholar
• Zhai W, Comai L. Repression of RNA polymerase I transcription by the tumor suppressor p53. Mol Cell Biol. 2000 Aug;20(16):5930–5938.
   PubMed Web of Science ®Google Scholar
• Hisatake K, Hasegawa S, Takada R, et al. The p250 subunit of native TATA box-binding factor TFIID is the cell-cycle regulatory protein CCG1. Nature. 1993 Mar 01;362(6416):179–181.
   PubMed Web of Science ®Google Scholar
• Lin CY, Tuan J, Scalia P, et al. The cell cycle regulatory factor TAF1 stimulates ribosomal DNA transcription by binding to the activator UBF. Curr Biol. 2002 Dec 23;12(24):2142–2146.
   PubMed Web of Science ®Google Scholar
• Neufeld TP, Edgar BA. Connections between growth and the cell cycle. Curr Opin Cell Biol. 1998 Dec;10(6):784–790.
   PubMed Web of Science ®Google Scholar
• Belfiore A, Malaguarnera R, Vella V, et al. Insulin Receptor Isoforms in Physiology and Disease: An Updated View. Endocr Rev. 2017 Oct 1;38(5):379–431.
   PubMed Web of Science ®Google Scholar
• Baker J, Liu JP, Robertson EJ, et al. Role of insulin-like growth factors in embryonic and postnatal growth. Cell. 1993 Oct 8;75(1):73–82.
   PubMed Web of Science ®Google Scholar
• Zhang H, Liu J, Li CR, et al. Deletion of Drosophila insulin-like peptides causes growth defects and metabolic abnormalities. Proc Natl Acad Sci U S A. 2009 Nov 17;106(46):19617–19622.
   PubMed Web of Science ®Google Scholar
• Oldham S, Stocker H, Laffargue M, et al. The Drosophila insulin/IGF receptor controls growth and size by modulating PtdInsP3 levels. Development. 2002;129(17):4103–4109.
   PubMed Web of Science ®Google Scholar
• Accili D, Drago J, Lee EJ, et al. Early neonatal death in mice homozygous for a null allele of the insulin receptor gene. Nat Genet. 1996 Jan;12(1):106–109.
   PubMed Web of Science ®Google Scholar
• Brogiolo W, Stocker H, Ikeya T, et al. An evolutionarily conserved function of the Drosophila insulin receptor and insulin-like peptides in growth control. Curr Biol. 2001 Feb 20;11(4):213–221.
   PubMed Web of Science ®Google Scholar
• Sun XJ, Wang L-M, Zhang Y, et al. Role of IRS-2 in insulin and cytokine signalling. Nature. 1995 Sep 01;377(6545):173–177.
   PubMed Web of Science ®Google Scholar
• Bohni R, Riesgo-Escovar J, Oldham S, et al. Autonomous control of cell and organ size by CHICO, a Drosophila homolog of vertebrate IRS1-4. Cell. 1999 Jun 25;97(7):865–875.
   PubMed Web of Science ®Google Scholar
• Leevers SJ, Weinkove D, MacDougall LK, et al. The Drosophila phosphoinositide 3-kinase Dp110 promotes cell growth. EMBO J. 1996;15(23):6584–6594.
   PubMed Web of Science ®Google Scholar
• Dummler B, Tschopp O, Hynx D, et al. Life with a single isoform of Akt: mice lacking Akt2 and Akt3 are viable but display impaired glucose homeostasis and growth deficiencies. Mol Cell Biol. 2006;26(21):8042–8051.
   PubMed Web of Science ®Google Scholar
• Chen WS, Xu PZ, Gottlob K, et al. Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. Genes Dev. 2001;15(17):2203–2208.
   PubMed Web of Science ®Google Scholar
• Verdu J, Buratovich MA, Wilder EL, et al. Cell-autonomous regulation of cell and organ growth in Drosophila by Akt/PKB. Nat Cell Biol. 1999 Dec 01;1(8):500–506.
   PubMed Web of Science ®Google Scholar
• Goberdhan DC, Paricio N, Goodman EC, et al. Drosophila tumor suppressor PTEN controls cell size and number by antagonizing the Chico/PI3-kinase signaling pathway. Genes Dev. 1999;13(24):3244–3258.
   PubMed Web of Science ®Google Scholar
• Potter CJ, Huang H, Xu T. Drosophila Tsc1 functions with Tsc2 to antagonize insulin signaling in regulating cell growth, cell proliferation, and organ size. Cell. 2001 May 4;105(3):357–368.
   PubMed Web of Science ®Google Scholar
• Zhang H, Stallock JP, Ng JC, et al. Regulation of cellular growth by the Drosophila target of rapamycin dTOR. Genes Dev. 2000;14(21):2712–2724.
   PubMed Web of Science ®Google Scholar
• Doble BW, Patel S, Wood GA, et al. Functional redundancy of GSK-3alpha and GSK-3beta in Wnt/beta-catenin signaling shown by using an allelic series of embryonic stem cell lines. Dev Cell. 2007 Jun;12(6):957–971.
   PubMed Web of Science ®Google Scholar
• Hoeflich KP, Luo J, Rubie EA, et al. Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation. Nature. 2000 Jul 01;406(6791):86–90.
   PubMed Web of Science ®Google Scholar
• Montagne J, Stewart MJ, Stocker H, et al. Drosophila S6 Kinase: A Regulator of Cell Size. Science. 1999;285(5436):2126–2129.
   PubMed Web of Science ®Google Scholar
• Hosaka T, Biggs WH 3rd, Tieu D, et al. Disruption of forkhead transcription factor (FOXO) family members in mice reveals their functional diversification. Proc Natl Acad Sci U S A. 2004;101(9):2975–2980.
   PubMed Web of Science ®Google Scholar